阿拉丁多款试剂助力新冠病毒药物研发---筛选治疗2019-nCoV潜在活性药物

来源: 上海阿拉丁生化科技股份有限公司   2020-3-9   访问量:480评论(0)

box-sizing: border-box; background-color: rgb(70, 163, 255); width: 203px;">包装E135556Efavirenz
依法韦仑≥98%(HPLC)154598-52-4 10mg,50mg,250mg,1g,5gA125825Atazanavir
阿扎那韦-198904-31-3 10mg,50mg,250mg,5gR126586利托那韦
Ritonavir≥98%155213-67-5 10mg,50mg,250mg,500mgD127014Danoprevir (ITMN-191)≥95%850876-88-9 2mg,5mg,25mgM124903MK-517298%1350514-68-9 5mg,10mgD127636多替拉韦
Dolutegravir≥99%1051375-16-6 5mg,10mg,50mgV127611VX-222 (VCH-222, Lomibuvir)≥99%1026785-59-05mg,10mg,50mgL299096洛比那韦
Lopinavir95%192725-17-010mg,50mg,250mg,1gL129320洛比那韦
Lopinavir≥99%192725-17-0 10mg,50mg,100mg,250mg,1gD125841达芦那韦
Darunavir98%206361-99-15mg,10mg,50mg,250mg,1gN137745奈非那韦
Nelfinavir Mesylate98%159989-65-8 10mg,50mg,250mgT126775Telaprevir
特拉匹韦≥98%402957-28-25mg,10mg,50mgA126552Abacavir
阿巴卡韦≥98.0%136470-78-5 1g,5gR129802Raltegravir(MK-0518)≥97%518048-05-0 5mg,10mg,50mg,1g

抑制新型冠状病毒(2019-nCoV)的2’-O-核糖 甲基转移酶的DTI预测结果

项目号中文名称规格CAS包装
E135556Efavirenz
依法韦仑
≥98%(HPLC)154598-52-4 10mg,50mg,250mg,1g,5g
A125825Atazanavir
阿扎那韦
-198904-31-310mg,50mg,250mg,5g

参考文献

Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model.

,
阿拉丁多款试剂助力新冠病毒药物研发---筛选治疗2019-nCoV潜在活性药物

新型冠状病毒(2019-nCoV)疫情正在迅速向全球蔓延。截止2020年3月6日,全球累计98373人, 累计死亡3388人。由于目前没有特效药可以治疗新冠肺炎,治疗新冠肺炎的药物研发迫在眉睫。通过以AI为架构的药物筛选手段,可以发现多种可能对2019-nCoV有治疗作用的药物及化合物。阿拉丁提供以下几十款试剂作为此药物研发的研发用材料。

韩国Deargen公司、美国佐治亚州亚特兰大市埃默里大学、韩国天安市担国大学自然科学学院联,利用药物-靶点相互作用模型(MT-DTI),预测了与新型冠状病毒(2019-nCoV) 3C样蛋白酶、RNA依赖RNA聚合酶、解旋酶、3 '- 5 '核酸外切酶、内切RNA酶、内切RNA酶的药物及化合物。

抑制新型冠状病毒(2019-nCoV) 3C样蛋白酶的DTI预测结果

项目号产品名称纯度CAS规格
A125825Atazanavir
阿扎那韦
-198904-31-310mg,50mg,250mg,5g
E135556Efavirenz
依法韦仑
≥98%(HPLC)154598-52-4 10mg,50mg,250mg,1g,5g
R126586利托那韦
Ritonavir
≥98%155213-67-5 10mg,50mg,250mg,500mg
D127636多替拉韦
Dolutegravir
≥99%1051375-16-6 5mg,10mg,50mg
A126103Asunaprevir
阿那匹韦
≥98%630420-16-5 5mg,10mg,50mg,250mg
S127117 Simeprevir
西咪匹韦
≥99%923604-59-5 5mg,10mg,50mg,100mg

抑制新型冠状病毒(2019-nCoV)的RNA依赖RNA聚合酶的DTI预测结果

项目号产品名称纯度CAS规格
M124903 MK-517298%1350514-68-9 5mg,10mg
G129109Ganciclovir
更昔洛韦
≥98.0%82410-32-0 1g,5g,25g,100g
A125825Atazanavir
阿扎那韦
-198904-31-310mg,50mg,250mg,5g
D127186Daclatasvir(BMS-790052)≥98%1009119-64-510mg,50mg,250mg
E126710Etravirine (TMC125)≥95%269055-15-4 5mg,25mg,100mg,1g
E181466Entecavir
恩替卡韦
98%142217-69-4 250mg,1g
E135556Efavirenz
依法韦仑
≥98%(HPLC)154598-52-4 10mg,50mg,250mg,1g,5g
A126103Asunaprevir
阿那匹韦
≥98%630420-16-5 5mg,10mg,50mg,250mg
A126552Abacavir
阿巴卡韦
≥98.0%136470-78-5 1g,5g
D127636多替拉韦
Dolutegravir
≥99%1051375-16-6 5mg,10mg,50mg
V127611VX-222 (VCH-222, Lomibuvir)≥99%1026785-59-05mg,10mg,50mg
P125160Penciclovir
喷昔洛韦
≥99%39809-25-150mg,250mg,1g
D127014Danoprevir (ITMN-191)≥95%850876-88-9 2mg,5mg,25mg
R126586利托那韦
Ritonavir
≥98%155213-67-5 10mg,50mg,250mg,500mg
S126514沙奎那韦
Saquinavir
≥98%127779-20-8 25mg,100mg
R129802Raltegravir(MK-0518)≥97%518048-05-0 5mg,10mg,50mg,1g

抑制新型冠状病毒(2019-nCoV)的解旋酶的DTI预测结果

项目号中文名称规格CAS包装
S127117 Simeprevir
西咪匹韦
≥99%923604-59-5 5mg,10mg,50mg,100mg
A125825Atazanavir
阿扎那韦
-198904-31-310mg,50mg,250mg,5g
M124903 MK-517298%1350514-68-9 5mg,10mg
A126103Asunaprevir
阿那匹韦
≥98%630420-16-5 5mg,10mg,50mg,250mg
T126775Telaprevir
特拉匹韦
≥98%402957-28-25mg,10mg,50mg
R126586利托那韦
Ritonavir
≥98%155213-67-5 10mg,50mg,250mg,500mg
L299096洛比那韦
Lopinavir
95%192725-17-010mg,50mg,250mg,1g
L129320洛比那韦
Lopinavir
≥99%192725-17-0 10mg,50mg,100mg,250mg,1g
D125841达芦那韦
Darunavir
98%206361-99-15mg,10mg,50mg,250mg,1g
G129109Ganciclovir
更昔洛韦
≥98.0%82410-32-0 1g,5g,25g,100g
P125160Penciclovir
喷昔洛韦
≥99%39809-25-150mg,250mg,1g
E126710Etravirine (TMC125)≥95%269055-15-4 5mg,25mg,100mg,1g
R129802Raltegravir(MK-0518)≥97%518048-05-0 5mg,10mg,50mg,1g
D127636多替拉韦
Dolutegravir
≥99%1051375-16-6 5mg,10mg,50mg
N137745奈非那韦
Nelfinavir Mesylate
98%159989-65-8 10mg,50mg,250mg
E135556Efavirenz
依法韦仑
≥98%(HPLC)154598-52-4 10mg,50mg,250mg,1g,5g
E181466Entecavir
恩替卡韦
98%142217-69-4 250mg,1g
R126586利托那韦
Ritonavir
≥98%155213-67-5 10mg,50mg,250mg,500mg
V127611VX-222 (VCH-222, Lomibuvir)≥99%1026785-59-05mg,10mg,50mg

抑制新型冠状病毒(2019-nCoV)的3 '- 5 '核酸外切酶的DTI预测结果

项目号中文名称规格CAS包装
S127117Simeprevir
西咪匹韦
≥99%923604-59-5 5mg,10mg,50mg,100mg
E135556Efavirenz
依法韦仑
≥98%(HPLC)154598-52-4 10mg,50mg,250mg,1g,5g
D127014Danoprevir (ITMN-191)≥95%850876-88-9 2mg,5mg,25mg
G129109Ganciclovir
更昔洛韦
≥98.0%82410-32-0 1g,5g,25g,100g
P125160Penciclovir
喷昔洛韦
≥99%39809-25-150mg,250mg,1g
A125825Atazanavir
阿扎那韦
-198904-31-310mg,50mg,250mg,5g
E181466Entecavir
恩替卡韦
98%142217-69-4 250mg,1g
D127186Daclatasvir(BMS-790052)≥98%1009119-64-510mg,50mg,250mg
M124903 MK-517298%1350514-68-9 5mg,10mg
A126103Asunaprevir
阿那匹韦
≥98%630420-16-5 5mg,10mg,50mg,250mg
R126586利托那韦
Ritonavir
≥98%155213-67-5 10mg,50mg,250mg,500mg
V127611VX-222 (VCH-222, Lomibuvir)≥99%1026785-59-05mg,10mg,50mg
D125841达芦那韦
Darunavir
98%206361-99-15mg,10mg,50mg,250mg,1g
R129802Raltegravir(MK-0518)≥97%518048-05-0 5mg,10mg,50mg,1g
D127636多替拉韦
Dolutegravir
≥99%1051375-16-6 5mg,10mg,50mg
L299096洛比那韦
Lopinavir
95%192725-17-010mg,50mg,250mg,1g
L129320洛比那韦
Lopinavir
≥99%192725-17-0 10mg,50mg,100mg,250mg,1g

抑制新型冠状病毒(2019-nCoV)的内切RNA酶的DTI预测结果

项目号中文名称规格CAS 上海阿拉丁生化科技股份有限公司   商家主页

地址:上海市浦东新区新金桥路196号6楼
联系人:丁博士
电话:400-620-6333
传真:021-50323701
Email:sale@aladdin-e.com